Scientists at National Institute of Immunology (NII) at New Delhi are trying to address the questions pertaining to vaccine development for COVID-19. NII is addressing the questions by applying the advanced human immunology investigations on the COVID-19 patient’s samples. Research team at NII is ready with the advanced immunology setup for addressing these questions in COVID-19 patients.

The team is also actively working on developing the platform for evaluating the COVID-19 vaccine. The program is recently supported under the Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC) joint efforts in COVID-19 National Consortium. The efforts will be accelerated as soon as the patients’ samples are available from the DBT COVID-19 research Consortium constituted to collect the COVID-19 patients samples from around 8 clinical centers across the Delhi-NCR.

NII is actively progressing to support the development of vaccines for COVID-19. Vaccine is the most preferred preventive measures to protect from COVID-19. Several uncertainties and questions that need to be answered to evaluate a vaccine for human use, includes (i) What should be the criteria to qualify a vaccine candidate? (ii) What should be the mechanism of action of a good vaccine? & (iv) How long a will a particular vaccine provide the protective cover?

Contact details:
Dr. Amulya K Panda
E-mail: amulya@nii.ac.in